|
|
|
|
The Pharmafocus Interview: Elmar Schnee
Merck's head of pharmaceuticals on the advantages of a diverse business model and the maddening 'disaster' that is Germany's cost effectiveness body IQWIG Germany's Merck has the kind of business model that investors warm to during times of...
|
|
|
The Pharmafocus Interview: Elmar Schnee
Merck's head of pharmaceuticals on the advantages of a diverse business model and the maddening 'disaster' that is Germany's cost effectiveness body IQWIG Germany's Merck has the kind of business model that investors warm to during times of...
|
|
|
NICE makes end-of-life drugs more available
High-cost drugs that extend the lives of terminally ill patients will be more readily approved for NHS use, thanks to a change of approach from NICE.The body has altered its appraisal process to make more end-of life drugs available by...
|
|
|
NICE makes end-of-life drugs more available
High-cost drugs that extend the lives of terminally ill patients will be more readily approved for NHS use, thanks to a change of approach from NICE.The body has altered its appraisal process to make more end-of life drugs available by...
|
|
|
Most acute NHS trusts independent from government
More than half of all acute NHS trusts have now been awarded foundation status, making them free to operate outside government control.This month Central Manchester University Hospitals will become the 113th foundation trust - for the...
|
|
|
GSK halts political funding
GlaxoSmithKline will no longer make corporate political donations in a bid to make its dealings with governments more transparent and avoid accusations of lobbying.GSK, like a number of other pharma firms, has made political contributions...
|
|
|
GSK halts political funding
GlaxoSmithKline will no longer make corporate political donations in a bid to make its dealings with governments more transparent and avoid accusations of lobbying.GSK, like a number of other pharma firms, has made political contributions...
|
|
|
Most acute NHS trusts independent from government
More than half of all acute NHS trusts have now been awarded foundation status, making them free to operate outside government control.This month Central Manchester University Hospitals will become the 113th foundation trust - for the...
|
|
|
Reforms launched with call for action on European competitiveness
The European Commission has launched what it calls a 'renewed vision' for the European pharmaceutical industry, which includes plans to provide more information to patients and a plea to increase competitiveness.The Commission's vice...
|
|
|
Abraxis Biosciences launches Abraxane in Europe
US biotech company Abraxis BioScience has launched its innovative breast cancer treatment Abraxane in Europe.The drug is a variant on the commonly used treatment paclitaxel, but the science behind Abraxane makes it different from its...
|
